SANOFI AVENTIS-FRANCE - Wyniki wyszukiwania

Unia Europejska - norweski - EMA (European Medicines Agency)

kevzara

sanofi winthrop industrie - sarilumab - leddgikt, reumatoid - immunsuppressive - kevzara i kombinasjon med methotrexate (mtx) er indisert for behandling av moderat til alvorlig aktive revmatoid artritt (ra) hos voksne pasienter som har svart mangelfullt på, eller som er intolerante for én eller flere sykdom endre anti revmatiske narkotika (dmards). kevzara kan gis som monoterapi ved intoleranse mot mtx eller når behandling med mtx er upassende.

Unia Europejska - norweski - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter for dermatitt, unntatt kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Norwegia - norweski - Statens legemiddelverk

act-hib 10 mikrog

sanofi pasteur europe - haemophilus influensae type b polysakkarid konjugert med tetanustoksoid - pulver og væske til injeksjonsvæske, oppløsning - 10 mikrog

Norwegia - norweski - Statens legemiddelverk

amaryl 4 mg

sanofi-aventis norge (3) - glimepirid - tablett - 4 mg

Norwegia - norweski - Statens legemiddelverk

amaryl 1 mg

sanofi-aventis norge (3) - glimepirid - tablett - 1 mg

Norwegia - norweski - Statens legemiddelverk

amaryl 2 mg

sanofi-aventis norge (3) - glimepirid - tablett - 2 mg

Norwegia - norweski - Statens legemiddelverk

amaryl 3 mg

sanofi-aventis norge (3) - glimepirid - tablett - 3 mg